174 related articles for article (PubMed ID: 30964199)
1. Follicular psoriasis induced by pembrolizumab in a patient with advanced non-small-cell lung cancer.
Scarfì F; Lacava R; Patrizi A; Tartari F; Ravaioli GM; Veronesi G; Lambertini M; Dika E
Int J Dermatol; 2019 Aug; 58(8):e151-e152. PubMed ID: 30964199
[No Abstract] [Full Text] [Related]
2. Real-World Experience With Pembrolizumab in Patients With Advanced Lung Cancer.
Peng TR; Wu TW
Am J Ther; 2019; 26(4):e537-e538. PubMed ID: 30946046
[No Abstract] [Full Text] [Related]
3. Cytokine Release Syndrome with Pseudoprogression in a Patient with Advanced Non-Small Cell Lung Cancer Treated with Pembrolizumab.
Kogure Y; Ishii Y; Oki M
J Thorac Oncol; 2019 Mar; 14(3):e55-e57. PubMed ID: 30782385
[No Abstract] [Full Text] [Related]
4. Ulerythema Ophryogenes Mimicking Frontal Fibrosing Alopecia.
Jerjen R; Sinclair R; Meah N; Bhoyrul B
Dermatol Surg; 2021 Jul; 47(7):1024-1025. PubMed ID: 34167135
[No Abstract] [Full Text] [Related]
5. Psoriasis and psoriatic arthritis induced by nivolumab in a patient with advanced lung cancer.
Law-Ping-Man S; Martin A; Briens E; Tisseau L; Safa G
Rheumatology (Oxford); 2016 Nov; 55(11):2087-2089. PubMed ID: 27436004
[No Abstract] [Full Text] [Related]
6. Tracheoesophageal Fistula Caused by Successful Response to Pembrolizumab in a Patient With Squamous Cell Lung Cancer.
Wang H; Zhang L; Liu W
J Thorac Oncol; 2019 Jul; 14(7):e141-e143. PubMed ID: 31235036
[No Abstract] [Full Text] [Related]
7. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.
Herbst RS; Baas P; Kim DW; Felip E; Pérez-Gracia JL; Han JY; Molina J; Kim JH; Arvis CD; Ahn MJ; Majem M; Fidler MJ; de Castro G; Garrido M; Lubiniecki GM; Shentu Y; Im E; Dolled-Filhart M; Garon EB
Lancet; 2016 Apr; 387(10027):1540-1550. PubMed ID: 26712084
[TBL] [Abstract][Full Text] [Related]
8. Pembrolizumab for the treatment of PD-L1 positive advanced or metastatic non-small cell lung cancer.
Dang TO; Ogunniyi A; Barbee MS; Drilon A
Expert Rev Anticancer Ther; 2016; 16(1):13-20. PubMed ID: 26588948
[TBL] [Abstract][Full Text] [Related]
9. Complete Pathologic Response When Adding Pembrolizumab to Neoadjuvant Chemotherapy in Stage IIIA Non-Small-Cell Lung Cancer.
Hill A; Gong J; Wilczynski S; Mirza R; Erhunmwunsee L; Salgia R
J Oncol Pract; 2018 Sep; 14(9):569-571. PubMed ID: 30044685
[No Abstract] [Full Text] [Related]
10. Multiple sclerosis associated with pembrolizumab in a patient with non-small cell lung cancer.
Romeo MAL; Garassino MC; Moiola L; Galli G; Comi G; Martinelli V; Filippi M
J Neurol; 2019 Dec; 266(12):3163-3166. PubMed ID: 31586260
[No Abstract] [Full Text] [Related]
11. Esophagitis in Non-Small Cell Lung Carcinoma Treatment Caused by Pembrolizumab.
Yoshida S; Miyamoto S; Naruse H; Ito J; Kinosita K; Kudo T; Hatanaka K; Yamamoto Y; Sakamoto N
Am J Gastroenterol; 2020 Jan; 115(1):13. PubMed ID: 31356230
[No Abstract] [Full Text] [Related]
12. Fatal encephalopathy after pembrolizumab treatment for advanced non-small cell lung carcinoma.
Freitas C; Sampaio L; Fernandes G
J Neurooncol; 2019 Nov; 145(2):399-402. PubMed ID: 31506753
[No Abstract] [Full Text] [Related]
13. Fatal Airway Inflammation Induced by Pembrolizumab in a Patient With NSCLC.
Ogawa T; Miyata J; Maehara J; Inoue T; Betsuyaku T
J Thorac Oncol; 2019 Jan; 14(1):e9-e10. PubMed ID: 30579555
[No Abstract] [Full Text] [Related]
14. Pembrolizumab and Severe Hypertriglyceridemia Requiring Apheresis: An Immune-Related Adverse Event.
Thakker M; Quadri K; Desai A; Illyas W; Kim MY; Desai S; Rager C
J Oncol Pract; 2019 Nov; 15(11):613-614. PubMed ID: 31580769
[No Abstract] [Full Text] [Related]
15. Histologic Transformation in a Patient with Lung Cancer Treated with Chemotherapy and Pembrolizumab.
Hsu CL; Chen KY; Kuo SW; Chang YL
J Thorac Oncol; 2017 Jun; 12(6):e75-e76. PubMed ID: 28532567
[No Abstract] [Full Text] [Related]
16. Pitfalls and pearls in the diagnosis of monilethrix.
Leitner C; Cheung S; de Berker D
Pediatr Dermatol; 2013; 30(5):633-5. PubMed ID: 23834295
[TBL] [Abstract][Full Text] [Related]
17. Linear atrophoderma of Moulin: A rare entity.
Kharkar VD; Abak BA; Mahajan SA
Indian J Dermatol Venereol Leprol; 2018; 84(5):591-594. PubMed ID: 30106014
[No Abstract] [Full Text] [Related]
18. Successful Retreatment Using Pembrolizumab for Non-small-cell Lung Cancer After Severe Immune-related Hepatitis: A Case Report.
Kobayashi K; Nakachi I; Mitsuishi A; Arai D; Sakurai K; Masaki K; Chiyotani A; Takahashi H; Tahara T; Soejima K
Clin Lung Cancer; 2020 Jan; 21(1):e30-e32. PubMed ID: 31699508
[No Abstract] [Full Text] [Related]
19. Retreatment with pembrolizumab in advanced non-small cell lung cancer patients previously treated with nivolumab: emerging reports of 12 cases.
Fujita K; Uchida N; Kanai O; Okamura M; Nakatani K; Mio T
Cancer Chemother Pharmacol; 2018 Jun; 81(6):1105-1109. PubMed ID: 29675747
[TBL] [Abstract][Full Text] [Related]
20. [Facial skin like worm eaten wood].
Jansen T
MMW Fortschr Med; 2016 Feb; 158(2):7. PubMed ID: 26961014
[No Abstract] [Full Text] [Related]
[Next] [New Search]
